mushrooms
Doseology Expands into US Retail Market
VERNON, BC, July 14, 2022 /CNW/ – Doseology Sciences Inc. (CSE: MOOD) (OTCQB: DOSEF) (FSE: VU7) (“Doseology” or the “Company”), a life sciences company focused on mental health and wellness, is excited to announce it has signed a Sales Management Agreement with Alternative Sales Management to act as the Company’s national sales manager for its expansion into the United […]
Toronto, Ontario–(Newsfile Corp. – February 23, 2022) – Silo Wellness Inc. (CSE: SILO) (OTCQB: SILFF) (FSE: 3K70) (“Silo Wellness” or the “Company”), a leading global psychedelics company, today announces several corporate updates. On February 4, 2022, the Company completed its first Jamaican psilocybin retreat of 2022 entitled “Renew Your Purpose” (see press release of December […]
Psyched Wellness Successfully Completes Its Largest Extraction and Shipment of AME-1 to Asia
Toronto, Ontario–(Newsfile Corp. – July 22, 2021) – Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF) (FSE: 5U9) (the “Company” or “Psyched”), a life sciences company focused on the production and distribution of artisanal functional and psychedelic mushrooms, is pleased to announce that the company has completed its largest extraction of AME-1 to date, and has successfully shipped […]
Optimi Health Finalizes Planned Build-Out of Mushroom Production and Research Facility
VANCOUVER, British Columbia, April 27, 2021 (GLOBE NEWSWIRE) — Optimi Health Corp. (CSE: OPTI) (OTC: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), developers of a vertically integrated functional mushroom brand focused on the health and wellness sector, is pleased to offer an activity update at its 20,000 sq. ft. production and research facility in Princeton, British Columbia. […]
Psyched Wellness Initiates the Next Pre-Clinical Trial Study on AME-1
Toronto, Ontario–(Newsfile Corp. – April 27, 2021) – Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF) (FSE: 5U9) (“Psyched“) a life sciences company focused on the production and distribution of artisanal functional and psychedelic mushrooms, is pleased to announce that the company and its Clinical Research Organization partner, KGK Science, has commenced the next preclinical trial study with […]
There’s no Magic Answer to the Question, “Can I Patent Magic Mushrooms?”
“Patent pending” is a phrase you are likely familiar with. You have seen it stamped on the side of some doodad at the mall or heard it on the TV show that you are binge watching, and you think to yourself, “Wow, I wish I could invent something that everyone thinks is really cool”. Most […]
“Psychedelics” is a buzz word on Wall Street, but much like legal cannabis or bitcoin and blockchain a decade ago, it remains greatly misunderstood as the market emerges. There was a time when psychedelics were only perceived as part of the illicit drug culture. That stigma is disappearing. Loaded with promise, the burgeoning market includes […]
MagicMed: Bringing the Drug Candidate Library Model to Psychedelics
The psychedelics market is often described as “emerging”, “burgeoning”, and other similar words, and while certainly true to a large extent, investors shouldn’t think for a moment this is all new. It’s far from it. There are scores of clinical and preclinical data to leverage, most collected before the Controlled Substance Act was enacted in […]
Tryp Debuts on the Canadian Securities Exchange
Tryp Therapeutics Inc. (CSE: TRYP) began trading on the Canadian Securities Exchange (CSE) on December 18, 2020 under the ticker symbol “TRYP”. “Trading on the CSE is a significant milestone in Tryp’s mission to transform the treatment of neuropsychiatric diseases with safe and effective psychedelic medicine,” said CEO James Kuo, MD. “All of the […]
Pure Extracts Unveils Plans for Functional Mushrooms
There are more than 2,000 species of edible fungi and at least 15 have functional benefits that support overall health. Like other superfoods, functional mushrooms have antioxidant properties that support the immune system, dietary fiber to aid in healthy digestion and numerous other benefits to everything from mental clarity to skin health. At the […]
How the Psybrary™ Could Revolutionize Psychedelic Drug Discovery
The psychedelic drug market is projected to grow at a compound annual growth rate of 16.3% over the next eight years to reach $6.85 billion by 2026, according to Data Bridge Market Research. With the potential to treat a wide range of mental health disorders, several organizations are already conducting clinical trials in the space. […]
Cybin Corp.: A Psychedelics Pioneer Led by a Biotech Veteran
Cybin has become one of the most popular psychedelic companies over the past year. With a unique approach to the market and an experienced management team, the company aims to bring a breakthrough psychedelic therapy to market for those suffering from Major Depressive Disorder and other mental health conditions—and build value for shareholders in the […]
Cybin Corp.: A Diversified Play on Psychedelic Therapeutics
More than 700 million people around the world suffer from a mental illness, addiction or eating disorder, according to the World Health Organization, which costs the global economy $2.5 trillion each year in direct and indirect costs. Despite these significant costs, large pharmaceutical companies have stopped searching for the next Prozac. Psychedelics, including psilocybin, […]
What Are Functional Mushrooms?
Most people think of white buttons at the grocery store when they think of mushrooms, but in reality, there are hundreds of different kinds of mushrooms. Functional mushrooms—like functional foods and beverages—are mushroom varieties that provide a health benefit, ranging from run-of-the-mill vitamins and minerals to important nutrients, including selenium, potassium, riboflavin, niacin, proteins, […]
Ehave, Inc. Appoints Dr. Mark Braunstein as Chief Psychedelic Officer
Dr. Braunstein is recognized worldwide in Psychedelic Psychiatry, which entails treating psychiatric disorders with psychedelics Dr. Braunstein is a renowned expert on psychedelic therapy and addiction. As a pioneer in psychedelic medicine research, he specializes in the treatment of ADHD, depression, anxiety, bipolar disorder, substance abuse, oppositional defiance, personality disorders, and treatment resistance. He has […]
Psychedelics: Investing in the Perfect BrainStorm
Psychedelics are rapidly becoming both a mainstream treatment option and investment opportunity. With growing interest among researchers, forward-thinking companies are starting to build a presence in the space. In this article, we will take a look at the growing body of therapeutic evidence for psychedelics. How decriminalization is gaining ground, and how Ehave Inc. (OTC: […]
5 Ways to Participate in the Psychedelics Boom
The psychedelics industry is quickly becoming the next frontier market for investors as the cannabis industry matures. Through a combination of cutting-edge research and decriminalization, investors are hoping that the industry moves in the same direction as medical cannabis over the coming years. Let’s take a look at five public companies in the space and […]
The Yield Growth Corp. Keeps Growing Like a Weed…or a Mushroom
While some companies are scratching their heads about what to make of the brutal treatment cannabis stocks have felt this year, The Yield Growth Corp. (CSE: BOSS)(OTCQB: BOSQF) seems undaunted, expanding its cannabis business while rapidly emerging as a leading public company in the mushroom space. Click here to receive an investor deck and corporate […]
Search CannabisFN
Press Coverage
Psychedelics Index
Top Videos
Matthew Nordgren is an ambitious executive, dedicated philanthropist, and accomplished athlete who brings a unique passion to creating strategic alliances. He has breadth and depth of experience in finance, corporate development, and capital sourcing, as well as in building highly motivated teams of skilled professionals. In 2005, Mr. Nordgren received his education at the University […]
Technical420 is the premier provider of research and analysis on cannabis stocks. We provide investors with sponsored and non-sponsored information on the volatile and emerging cannabis industry. “Our research is our passion!” Your profit is our reward!
Harborside Inc. (CSE: HBOR) is one of the oldest, largest and most respected cannabis retailers in the world with award-winning flower, concentrates, edibles and other cannabis products from California’s most respected growers and manufacturers.
Red White & Bloom Inc. (CSE: RWB) is positioning itself to be one of the top three multi-state cannabis operators active in the U.S. legal cannabis and hemp sector.
Network Partners
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.
Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer
